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Abstract
A number of studies have demonstrated an association of neuropathic pain and chronic low back pain (CLBP), but the outcome
difference in each medical management is poorly understood. This study is aimed to investigate treatment patterns of neuropathic
pain in CLBP patients and to explore patient-reported outcomes (PROs) including quality of life (QoL) and functional disability by
treatment patterns.
Data were extracted from the neuropathic low back pain (NLBP) outcomes research. It was a multicenter and cross-sectional
study in which 1200 patients were enrolled at 27 general hospitals, from 2014 to 2015. Of total, 478 patients classiﬁed as neuropathic
pain were used for this subgroup analysis. The patients were divided into 2 groups according to treatment patterns (with vs. without
the targeted therapy [TT] of neuropathic pain). Demographic and clinical features were collected by chart reviews and PROs were
measured by patient’s survey. QoL was assessed by EuroQoL 5-dimension (EQ-5D) questionnaire. Functional disability was
measured by the Quebec Back Pain Disability Scale (QBPDS). Multiple linear regression analyses were conducted to compare the
PROs between TT group and non-targeted therapy (nTT) group.
Among the NLBP patients (mean age 63years, female 62%), EQ-5D index, EuroQoL-Visual Analog Scale (EQ-VAS), and QBPDS
Scores (mean±standard deviation) were 0.40±0.28, 54.98±19.98, and 46.03±21.24, respectively. Only 142 (29.7%) patients hadEditor: Mirko Manchia.
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Hong et al. Medicine (2018) 97:35 Medicinepharmacological TT of neuropathic pain. Univariate analyses revealed no signiﬁcant mean differences between TT group and nTT
group in the EQ-5D index (0.41±0.27 and 0.39±0.28), EQ-VAS (56.43±18.17 and 54.37±20.69), and QBPDS (45.31±21.32 and
46.31±21.24). After adjustment with covariates, TT group had higher scores of EQ-5D index (b = 0.07; P<0.01) and EQ-VAS (b =
4.59; P<0.05) than the nTT group. The TT group’s QBPDS score was lower than the nTT group, although its statistical signiﬁcance
still has not been reached (b = 4.13; P=0.07).
We found that considerable proportion of the NLBP patients remains untreated or undertreated. Although TT group had
signiﬁcantly better QoL than nTT group, only 29.7% of NLBP patients had pharmacological TT. Therefore, clinicians should consider
using TT for better QoL of neuropathic pain patients.
Abbreviations: CLBP = chronic low back pain, DN4 = Douleur Neuropathique 4, EQ-5D = EuroQoL 5-dimension, EQ-VAS =
EuroQoL Visual Analogue Scale, JOABPEQ = Japanese Orthopedic Association Back Pain Evaluation Questionnaire, LBP = low
back pain, NLBP = neuropathic low back pain, nTT = non-targeted therapy, OR = outcome research, PRO = patient-reported
outcomes, QBPDS = Quebec Back Pain Disability Scale, QoL = quality of life, QTFC-SD = Quebec Task Force Classiﬁcation for
Spinal Disorders, RCTs = randomized controlled trials, SF-36 = Short Form 36, TCAs = tricyclic antidepressants, TT = targeted
therapy, VAS = visual analog scale.
Keywords: chronic low back pain, neuropathic pain, pharmacological targeted therapy, quality of life[24]1. Introduction
Low back pain (LBP) is one of the most common musculoskeletal
disorders, resulting in signiﬁcant personal, social, and economic
burden.Mechanical conditions of the spine, including disk disease,
disk herniation, spondylosis, spinal stenosis, and fractures,
account for up to 98% of LBP cases. Neuropathic pain in chronic
LBP was reported to be highly prevalent and neuropathic pain
affects the social and psychological well-being of LBP patients.[1–
20] A recent systematic review to evaluate prevalence rate of the
neuropathic pain in LBP patients has reported prevalence ranging
from 29.4 to 73%.[1–20] In addition, the meta-analysis of 20
studies, including a total of 14,269 patients with LBP, found that
the pooled prevalence rate of neuropathic low back pain (NLBP)
was 47% (40%–54%).[21] Thus, NLBP may require to be
considered as an important clinical problem.
Neuropathic pain profoundly decreased the quality of life
(QoL).[22] Hiyama et al[18] reported that NLBP patients had
signiﬁcantly higher visual analog scale (VAS) scores and lower
the scores of short form 36 (SF-36) and Japanese Orthopedic
Association Back Pain Evaluation Questionnaire than LBP
patients with nociceptive pain. This result suggests that NLBP
affects the physical, social, and psychological well-being
compared to nociceptive LBP patients. Hence, it is signiﬁcant
to identify the involvement of neuropathic pain in LBP patients
and to effectively manage NLBP.
However, therewas nomulticenter cohort study not only for the
prevalence of NLBP patients but also for the treatment pattern in
Korean NLBP patients. Although treatment pattern and outcome
could be different in each different country and health care system,
it would be valuable to understand relationship between the
pattern and the outcome of NLBP treatment.
Pharmacotherapy is the primary clinical approach for managing
NLBP. Canadian pain society provided guidelines of pharmaco-
logical management of chronic neuropathic pain as follows: ﬁrst-
line treatments were speciﬁc antidepressants (tricyclics) and
anticonvulsants (gabapentin and pregabalin).[23] Serotonin nor-
adrenaline reuptake inhibitors and topical lidocaine were recom-
mended as second-line therapies. Third-line therapies included
tramadol and controlled release opioid analgesics. Recommended
forth-line treatments were cannabinoids, methadone, and anti-
convulsants. The special interest group of the international
association for the study of neuropathic pain recently suggested
guidelines of pharmacological management of neuropathic2pain. According to their guidelines, tricyclic antidepressants
(TCAs), gabapentin, pregabalin, and topical lidocaine were
recommended as ﬁrst-line treatment options and second-line
treatments included opioid analgesics and tramadol.
Although these guidelines for neuropathic pain management
were provided, there was still a lack of available data on
treatment patterns of NLBP patients and outcome by treatment
pattern.
Therefore, the purpose of this study was to investigate the
treatment patterns of NLBP in Korea and to explore the patient-
reported outcomes (PROs) including QoL and functional
disability by the treatment patterns.2. Materials and methods
2.1. Study design and population
This was a subgroup analysis of chronic low back pain (CLBP)
patients with neuropathic pain derived from the NLBP outcome
research (OR) that wasmulticentered, cross-sectional study. Data
were collected between December 2014 and May 2015 from 27
nationwide general hospitals of South Korea. This study was
approved by the all participated centers’ Institutional Review
Board. We included CLBP patients who have moderate degree of
LBP at least (VAS>4) and received “minimally adequate
treatment” with a medication trial lasting at least 4 weeks.
Patients judged by physicians to meet the following criteria were
included: age 20 years; CLBP at least 3 months; patients
diagnosed with LBP owing to herniated disc, stenosis, spondy-
losis, spondylolysis, spondylolisthesis, or degenerative disc
disease, according to magnetic resonance imaging or computed
tomography ﬁndings; VAS at least 4; pain medication at least 4
weeks before the enrollment; and patients who were able to
understand and willing to complete the subject information sheet
and informed consent form. If the patients had following criteria,
they were excluded: cancer, sprain, infection, fracture, ankylos-
ing spondylitis, myofascial pain, or sacroiliitis; surgery within 3
months; current participation in other interventional studies; or
patients with a critical or unstable health condition. The patients
were clearly informed about the aim of our study, and their
informed consents were obtained.
A target sample size was estimated based on the assumption
that the prevalence of NLBP is 37%.[3]With a signiﬁcance level of
0.05 and an estimated error rate of 2.8%, the required number of
Figure 1. Study design of this study. Among the total 1200 patients enrolled in neuropathic low back pain outcome research, neuropathic low back pain patients
whose scores were at least 4/10 in DN4 questionnaire were included in this subgroup analysis. CLBP=chronic low back pain, NP=neuropathic pain.
Hong et al. Medicine (2018) 97:35 www.md-journal.compatients to be enrolled was calculated to be approximately 1200:
n ¼ z21a=2Pð1 PÞ=d2½15ðP ¼ 0:37; z21a=2
¼ 1:962;whena is 0:05; d ¼ 0:028Þ:
Among the total 1200 patients enrolled in NLBP OR, NLBP
patients whose scores were at least 4/10 in Douleur Neuro-
pathique 4 (DN4) questionnaire were included in this subgroup
analysis (Fig. 1).
2.2. Study data
2.2.1. Baseline variables. Demographic and clinical features
were obtained through reviews ofmedical records and PRO (QoL
and functional disability) were measured by the patient’s survey.
Age, sex, height, and body weight were included in demographic
information. Clinical variables contained diagnosis of LBP,
comorbidities, symptom period, pain VAS scores, DN4 score,
Quebec Task Force Classiﬁcation for Spinal Disorders (QTFC-
SD), and pain control state (pharmacotherapy and surgery). As
one of clinical characteristics, QTFC-SD was used to categorize
patients’ spinal disorders on the basis of clinical examination and
pain localization.[25]
2.2.2. Treatment group. Treatment patterns were divided into 2
groups according to whether patients received targeted therapy
(TT) of neuropathic pain or not. The TT group included
anticonvulsants, TCAs, and topical lidocaine, whereas non-
targeted therapy (nTT) group included opioid analgesics,
nonopioid analgesics, and muscle relaxants.[26,27]
2.2.3. Outcomes. QoL was assessed by generic EuroQoL 5-
dimension (EQ-5D) questionnaire. EQ-5D is made up of 2 parts: a
descriptive system, which could be converted into a single index,
and a EuroQoL Visual Analogue Scale (EQ-VAS). The descriptive
measurement consists of 5 dimensions: “mobility," “self-care,"
“usual activities," “pain/discomfort," and “anxiety/depression."3Each dimension has 3 levels: no problems, some problems, and
severe problems, coded as numbers of 1, 2, and 3 in order. These
scores, measured by descriptive part, were converted into scores of
a single index (EQ-5D index) with a range from0.229 to 1 point
by applying the equation as follows:
Final EQ-5D index’s score[28]=1 – (0.165+0.003M2+
0.274M3+0.058SC2+0.078SC3+0.045UA2+
0.133UA3+0.048PD2+0.130PD3+0.043AD2+
0.103AD3+0.347N3+0.014 I2sq)
The EQ-VAS with a range from 0 to 100 points was used for
subjective evaluation of patient’s current health state. The ends of
the scale were marked “best imaginable health state” and “worst
imaginable health." In these 2 measurements, a higher score
means a higher QoL.
Quebec Back Pain Disability Scale (QBPDS) was used for
measuring functional disability. The QBPDS consists of 20
questions and has a scale of 0 to 5 for each question with a range
from 0 to 100 points. A higher score of this tool indicates a more
severe disability of function.2.3. Study ethics
This investigation was designed as multicenter cross-sectional
observational study of LBP patients. The patients (or their legal
representatives) were provided with all study-related informa-
tion, and they signed an informed consent form. All participating
medical institutions obtained approval from their respective
institutional review boards.2.4. Statistical analysis
Patient’s demographic and clinical characteristics were summa-
rized as mean± standard deviation (SD) for continuous variables
or frequency (percentage) for categorical variables. Comparisons
of patient’s characteristics between the TT group and nTT group
2Table 1
Demographic and clinical variables of patients with neuropathic chronic low back pain (n=478).
Total TT nTT
Variables N=478 N (%)=142 (29.7) N=336 (70.3) P
∗
Age, y, mean±SD 62.96±13.40 63.65±12.74 62.68±13.67 .4689
Sex, n (%) .7830
Female 294 (61.5) 86 (60.6) 208 (61.9)
Male 184 (38.5) 56 (39.4) 128 (38.1)
Comorbid disease, n (%) .6944
Yes 283 (59.2) 86 (60.6) 197 (58.6)
No 195 (40.8) 56 (39.4) 139 (41.4)
Pain VAS (scores), mean±SD 6.40±1.70 6.45±1.54 6.37±1.77 .6506
Pain duration, mo†, mean±SD 52.45±68.67 50.15±76.54 53.42±65.15 .7631
LBP period, mo†, mean±SD 15.44±23.60 18.30±22.62 14.03±23.99 <.0001
Detailed diagnosis‡, n (%)
Herniated disc 183 (38.3) 65 (45.8) 118 (35.1)
Stenosis 314 (65.7) 99 (69.7) 215 (64.0)
Spondylosis 39 (8.2) 17 (12.0) 22 (6.5)
Spondylolysis 12 (2.5) 3 (2.1) 9 (2.7)
Spondylolisthesis 74 (15.5) 19 (13.4) 55 (16.4)
Degenerative disc disease 48 (10.0) 10 (7.0) 38 (11.3)
QTFC-SD, n (%) <.0001
Pain without radiation 27 (5.7) 10 (7.1) 17 (5.1)
Pain with proximal extremity radiation 68 (14.2) 9 (6.3) 59 (17.6)
Pain with distal extremity radiation 238 (49.8) 70 (49.3) 168 (50.0)
Pain with radiation and neurologic ﬁnding 47 (9.8) 9 (6.3) 38 (11.3)
Spinal nerve root compression 41 (8.6) 21 (14.8) 20 (5.9)
Spinal stenosis 57 (11.9) 23 (16.2) 34 (10.1)
Nonpharmacological treatment, n (%) <.0001
Yes 37 (7.7) 4 (2.8) 33 (9.8)
No 441 (92.3) 138 (97.2) 303 (90.2)
Surgical intervention, n (%) <.0001
No surgery 268 (56.1) 73 (51.4) 195 (58.0)
Patients having surgery plan 82 (17.1) 19 (13.4) 63 (18.8)
Patients undergoing surgery 3 mo ago 128 (26.8) 50 (35.2) 78 (23.2)
LBP= low back pain, nTT=non-targeted therapy, QTFC-SD=Quebec Task Force Classiﬁcation for Spinal Disorders, SD= standard deviation, TT= targeted therapy, VAS= visual analogue scale.
∗
P values are from 2 independent sample t test or x2 test as appropriate
† A logarithmic transformed values were used for the independent t test to compare TT and nTT groups.
‡Multiple responses item.
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appropriate. Mean differences of patient’s QoLmeasured by EQ-
5D index and EQ-VAS scores as well as their functional disability
measured by QBPDS were also examined using the independent t
test. An appropriateness of a use of the test was examined by
histogram and normal probability plot for each of numerical
variables. For variables with positively skewed data, a logarith-
mic transformation was performed before the t test. Multiple
linear regression analyses were performed to compare scores of
EQ-5D index, EQ-VAS, and QBPDS between 2 groups after
adjusting potential confounders. Variables with P< .1 from
bivariate analyses were selected as the potential confounders.
Degree of performance of the regression model was measured by
its coefﬁcient of determination (R2). Collinearity among
explanatory variables has also been checked, and no noticeable
problem found in the multiple regression models used in this
study. All statistical analyses were performed using the SAS
software, version 9.4 (SAS Institute Inc., Cary, NC), and a 2-
tailed P value <.05 was considered as statistically signiﬁcant.
3. Results
3.1. Characteristics of the NLBP patients
Demographic and clinical features of NLBP patients are
presented in Table 1. Of a total 478 patients with NLBP, 2944(61.5%) patients were females and mean age was 62.96±13.40
years. The most common type of spinal disease was stenosis
(65.7%), followed by herniated disc (38.3%) and spondylolis-
thesis (15.5%). By the QTFC-SD category, the pain with distal
extremity radiation was the most (49.8%). Only 142 (29.7%)
patients had pharmacological TT of neuropathic pain. There
were not signiﬁcantly difference between the TT group and the
nTT group in terms of age, sex ratio, comorbid diseases, pain
VAS, and pain duration. LBP period of TT group (18.30±22.62
months) was signiﬁcantly longer than the nTT group (14.03±
23.99 months). The QTFC-SD items showed signiﬁcant differ-
ence among the groups (P< .0001). In the TT group, the most
frequent pain type was pain with distal extremity radiation
(49.3%) followed by spinal stenosis (16.2%) and spinal nerve
root compression (14.8%). pain with distal extremity radiation
(50.0%) showed the highest proportion in the nTT group as in
the TT group. However, unlike the TT group, pain with proximal
extremity radiation (17.6%) was the secondly highest, followed
by pain with radiation and neurologic ﬁnding (11.3%).
Our data also showed that the subject’s severity of LBP
measured by QBPDS was associated with their anxiety/depres-
sion which was the ﬁfth dimension of EQ-5D index measured as
“none,” “some/moderate,” and “extreme.” Speciﬁcally, patient
having more severe anxiety/depression showed signiﬁcantly
higher mean QBPDS score (P< .0001).
Figure 2. Patient-reported outcome scores in patients with neuropathic chronic low back pain. There were no differences in the EQ-5D index, EQ-VAS and
QBPDS between two groups (TT and nTT) in the student t-tests. However, the multiple linear regression analysis showed that EQ-5D index scores and
EQ-VAS scores were signiﬁcantly higher in the patients managed by the TT (b=0.07; P<0.01,b=4.59; P<0.05 respectively) than the nTT group. The patients
who received TT tended to have lower QBPDS scores (b=4.13; P=0.07), compared to the nTT group. EQ-5D=EuroQoL 5-dimension, EQ-VAS=EuroQoL
Visual Analogue Scale, nTT=non-targeted therapy, QBPDS=Quebec Back Pain Disability Scale, SD=standard deviation, TT= targeted therapy, VAS=visual
analogue scale.
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In NLBP patients, mean scores of EQ-5D index, EQ-VAS, and
QBPDS were 0.40±0.28, 54.98±19.98, and 46.03±21.24,
respectively (Fig. 2). In the student t tests, performed to identify
differences of PRO among 2 groups (TT and nTT), there were no
differences in the EQ-5D index (0.41±0.27 and 0.39±0.28),
EQ-VAS (56.43±18.17 and 54.37±20.69), and QBPDS (45.31
±21.32 and 46.31±21.24) (Fig. 2).
In the multiple linear regression analyses adjusting with
potential confounders (age, sex, duration of LBP, QTFC-SD
category, comorbidities, scores of DN4, and scores of pain VAS),
the patients managed by the TT showed higher scores of EQ-5D
index (b=0.07; P< .01) (Table 2) and EQ-VAS scores (b=4.59;Table 2
Effect of targeted therapy on patient’s quality of life measured by Euro
with multiple linear regression analysis.
Variables Coeff.
NP patients, TT group 0.0707
Age, y 0.0023
Sex, male 0.0621
LBP duration after diagnosis, mo 0.0007
QTFC-SD
Pain with proximal extremity radiation 0.0460
Pain with distal extremity radiation 0.0259
Pain with radiation and neurologic ﬁnding 0.0542
Spinal nerve root compression 0.0195
Spinal stenosis 0.0046
Comorbidities, yes 0.0136
DN4 (Scores) 0.0307
Pain VAS (scores) 0.0755
Coeff.=coefﬁcient, DN4=Douleur Neuropathique 4, LBP= low back pain, NP=neuropathic pain, QTF
standardized coefﬁcient, TT= targeted therapy, VAS= visual analogue scale. Reference category: NP pati
Model R2=33.9%.
5P< .05) (Table 3) than the nTT group. The patients who received
TT tended to have lower QBPDS scores (b=4.13; P= .07)
(Table 4), compared to the nTT group.4. Discussion
This study showed the mismatch between diagnosis and
treatment pattern of NLBP patients. Although 39.8% of LBP
patients met the DN4 criteria for neuropathic pain, only 29.7%
were receiving pharmacological treatment with proven efﬁcacy in
neuropathic pain. The literature reveals that neuropathic pain
is often undertreated or treated with ineffective or untested
modalities.Qol-5dimensions index score after adjusting potential confounders
SE Std. Coeff. P
0.0269 0.1208 .0088
0.0010 0.1057 .0288
0.0259 0.1100 .0169
0.0006 0.0588 .2126
0.0719 0.0552 .5228
0.0641 0.0469 .6864
0.0755 0.0563 .4737
0.0740 0.0208 .7922
0.0710 0.0056 .9484
0.0264 0.0242 .6065
0.0090 0.1609 .0007
0.0075 0.4719 <.0001
C-SD=Quebec Task Force Classiﬁcation for Spinal Disorders, SE= standard error, Std. Coeff.=
ents (non-targeted therapy group), sex (female), QTFC-SD (pain without radiation), comorbidities (no).
Table 3
Effect of targeted therapy on patient’s quality of lifemeasuredby EuroQol-visual analogue scale after adjusting potential confounderswith
multiple linear regression analysis.
Variables Coeff. SE Std. Coeff. P
NP patients, TT group 4.5933 2.3117 0.1063 .0477
Age, y 0.0658 0.0900 0.0410 .4649
Sex, male 1.4553 2.2285 0.0349 .5142
LBP duration after diagnosis, mo 0.0214 0.0472 0.0248 .6510
QTFC-SD
Pain with proximal extremity radiation 0.2700 6.2248 0.0044 .9654
Pain with distal extremity radiation 6.0399 5.5478 0.1486 .2771
Pain with radiation and neurologic ﬁnding 9.6431 6.4856 0.1389 .1380
Spinal nerve root compression 0.3866 6.4094 0.0056 .9519
Spinal stenosis 4.2575 6.1546 0.0703 .4896
Comorbidities, Yes 0.7273 2.2648 0.0176 .7483
DN4 (Scores) 0.8215 0.7765 0.0583 .2909
Pain VAS (scores) 2.8657 0.6446 0.2432 <.0001
Coeff.=coefﬁcient, DN4=Douleur Neuropathique 4, LBP= low back pain, NP=neuropathic pain, QTFC-SD=Quebec Task Force Classiﬁcation for Spinal Disorders, SE= standard error, Std. Coeff.=
standardized coefﬁcient, TT= targeted therapy, VAS= visual analogue scale. Reference category: NP patients (non-targeted therapy group), sex (female), QTFC-SD (pain without radiation), comorbidities (no).
Model R2=8.%
Hong et al. Medicine (2018) 97:35 MedicineA reason for the low proportion of patients having TT would
be difﬁculty in distinguishing the certain clinical difference
between NLBP and nociceptive LBP. Identifying the underlying
mechanism of chronic pain allows the use of pharmacological
agents targeting speciﬁc pain mechanisms.[29] NLBP results from
a primary lesion or a malfunction within the somatosensory
system, whereas nociceptive LBP is caused by tissue injury and/or
inﬂammatory process.[30] The general clinical diagnosis of
neuropathic pain was based on the evidence of a lesion or a
disease of the nervous system, which was ascertained by
interviewing the patients and performing clinical examinations.
However, it is complex and difﬁcult methods to detect
neuropathic pain in LBP patients.
Some clinicians used screening tools of neuropathic pain as a
simpler means. However, there were various standardized
screening measurements incurring wide variation in diagnosis
of neuropathic pain and no consensus on the diagnosis of
neuropathic pain.
In addition, although there were many evidence-based guide-
lines in the pharmacological management of neuropathic painTable 4
Effect of targeted therapy on patient’s functional disability measured b
confounders with multiple linear regression analysis.
Variables Coeff.
NP patients, TT group 4.1342
Age, y 0.3089
Sex, male 8.7176
LBP duration after diagnosis, mo 0.0712
QTFC-SD
Pain with proximal extremity radiation 4.2244
Pain with distal extremity radiation 0.8659
Pain with radiation and neurologic ﬁnding 1.7938
Spinal nerve root compression 1.9055
Spinal stenosis 1.2947
Co-morbidities, Yes 0.5652
DN4 (Scores) 1.5182
Pain VAS (scores) 4.8950
Coeff.=coefﬁcient, DN4=Douleur Neuropathique 4, LBP= low back pain, NP=neuropathic pain, QTF
standardized coefﬁcient, TT= targeted therapy, VAS= visual analogue scale. Reference category: NP pati
Model R2=28.4%.
6due to the attempts for developing a therapeutic approach of
related societies, neuropathic pain treatment guideline for LBP
was absent.
Canadian pain society provided guidelines of pharmacological
management of chronic neuropathic pain as follows: ﬁrst-line
treatments were speciﬁc antidepressants (tricyclics) and anti-
convulsants (gabapentin and pregabalin).[23] Serotonin nor-
adrenaline reuptake inhibitors and topical lidocaine were
recommended as second-line therapies. Third-line therapies
included tramadol and controlled release opioid analgesics.
Recommended forth-line treatments were cannabinoids, metha-
done, and anticonvulsants. The special interest group of the
international association for the study of neuropathic pain
recently suggested guidelines of pharmacological management of
neuropathic pain.[24] According to their guidelines, TCAs,
gabapentin, pregabalin, and topical lidocaine were recommended
as ﬁrst-line treatment options and second-line treatments
included opioid analgesics and tramadol.
We deﬁned the TT and nTT based on these 2 references. Target
therapy included TCAs, gabapentin, pregabalin, and topicaly Quebec Back Pain Disability Scale score after adjusting potential
SE Std. Coeff. P
2.2776 0.0888 .0704
0.0874 0.1812 .0005
2.1589 0.1969 <.0001
0.0453 0.0786 .1167
6.1035 0.0639 .4894
5.4153 0.0200 .8731
6.3971 0.0235 .7793
6.2397 0.0257 .7603
5.9710 0.0202 .8285
2.2022 0.0128 .7976
0.7559 0.1005 .0454
0.6154 0.3956 <.0001
C-SD=Quebec Task Force Classiﬁcation for Spinal Disorders, SE= standard error, Std. Coeff.=
ents (non-targeted therapy group), sex (female), QTFC-SD (pain without radiation), comorbidities (no).
Hong et al. Medicine (2018) 97:35 www.md-journal.comlidocaine, which are recommended as ﬁrst- or second-linemedical
treatment because their efﬁcacy in neuropathic pain has been
established in multiple randomized controlled trials (RCTs).
Neuropathic pain patients had severe and chronic symptoms
that impaired their QoL.[31,32] QoL measured by EQ-5D scores
of patients with neuropathic pain (0.40±0.28) was considerably
lower in this study than those of other chronic diseases reported
in the previous study (hypertension: 0.81,[33] 0.87–0.89;[34]
cardiovascular disease: 0.74,[33] 0.62–0.72;[35] diabetes: 0.82,[33]
0.83;[36] cancer: 0.86;[36] chronic kidney disease: 0.885;[37]
rheumatoid arthritis: 0.83,[36] 0.67–0.73[38]), which showed the
negative impact of the neuropathic pain in CLBP patients. After
adjustment with covariates, the patients managed by pharmaco-
logical TT showed higher EQ-5D index and EQ-VAS scores than
the nTT group, which suggested that the neuropathic pain
patients who received the TT showed signiﬁcantly better outcome
in terms of pain control and QoL than the nTT group. In many
RCTs, medications included in TT group of our study were
proven in terms of efﬁcacy of neuropathic pain therapy. Two
studies of antidepressants in neuropathic pain reported that
TCAs provided the identical efﬁcacy in the neuropathic pain
management.[39,40] Gabapentin and pregabalin have shown the
efﬁcacy in the studies on comparison between anticonvulsants
and placebo in patients with several neuropathic pain con-
ditions.[41,42] The 5% lidocaine patch has shown excellent
efﬁcacy and tolerability in allodynia patients due to various types
of peripheral neuropathic pain.[41,42]
This study has several limitations. First, some of the well-
known risk factors for NLBP include advanced age, female sex,
and diabetes with or without hypertension, obesity, smoking, and
psychological factors such as depression. Although these data
demonstrated that neuropathic LBP and depression are signiﬁ-
cantly correlated with each other, the relationship between
neuropathic LBP and other risk factors was not examined in this
study because the aim of this study was to investigate treatment
patterns of NLBP patients and to explore PRO including QoL
and functional disability by treatment patterns.
Second limitation of this study stems from the differential
diagnosis of neuropathic pain. This study usedDN4 questionnaire
to diagnose a neuropathic pain in LBP patients based on a more
reliable identiﬁcation and qualiﬁcation of a neuropathic pain.
Despite the good sensitivity and speciﬁcity of the DN4 question-
naire, the question remains whether the distinction between
neuropathic and nociceptive symptom proﬁles truly represents the
biological background of pain, or whether it may be an artiﬁcial
effect. Moreover, these categories of pain overlap to some degree.
Although screening tools may give guidance to clinicians by
selecting patients that need further diagnostic evaluation and pain
management by specialists, they clearly do not replace clinical
judgment. In this regard, the evaluation method using the
questionnaire that was employed in this study is also a limitation.
In addition, it should be noted that because other pain
measures were not part of the study, no comparisons can bemade
between the DN4 questionnaire and other neuropathic pain
screening scales.
The third limitation of this study results from the subject
population because it was mostly performed at a tertiary care
university hospital. The spectrum of presenting patients
obviously differs between primary care clinics and community
hospitals. Fourth, this subgroup analysis has the limitation on the
sample size, not calculated to investigate this subgroup. Thus, it is
difﬁcult to generalize the study results. Lastly, we could use only
measured variables in this study as the potential confounders.7Despite these limitations, there have been no other similar
studies to compare the treatment outcome between TT and
nTT in the NLBP population and this study showed that TT
could be associated with a better QoL of NLBP patients. There
were, however, relatively low numbers of patients having
pharmacological TT of neuropathic pain in this study. These
results could suggest that in cases with neuropathic pain,
appropriate pharmacological treatments for the neuropathic
component should be considered to have better QoL. Further
studies are required to explore effects of TT on the
improvement of QoL and functional ability in larger popula-
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